Company: EUDAW
Filing Date: 2025-06-24
Form Type: 424B5
Source: 0001641172-25-016185
Chunk: 20

Company: EUDA Health Holdings Ltd
Filing Date: 2025-06-24
Form: 424B5
Chunk 20
---
23, 2025, and exclude the following:

| ● | 37,516                                                                                                                           
 of our ordinary shares issuable upon conversion of convertible notes in the aggregate principal amount of $53,402 as of June 23, 
 2025 at a weighted-average exercise price of $1.42 per share.                                                                    |
| ● | 4,458,625                                                                                                                        
 of our ordinary shares issuable upon exercise of an aggregate of 8,917,250 outstanding warrants at a weighted-average exercise   
 price of $11.50 per share.                                                                                                       |

| S-12 |

<div align='center'>DIVIDEND POLICY</div>

We have never paid or declared any cash dividends on our ordinary shares. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future.

| S-13 |

<div align='center'>PLAN OF DISTRIBUTION</div>

We entered into a Sales Agreement dated June 23, 2025, with Chardan, relating to shares of our ordinary shares offered by this prospectus supplement and the accompanying prospectus. Under the Sales Agreement, we may issue and sell our ordinary shares having aggregate sales proceeds of up to $10.0 million from time to time through the Agent, subject to certain limitations, including the number of shares registered under the registration statement to which this prospectus supplement relates. The form of the Sales Agreement will be filed as an exhibit to a report filed under the Exchange Act and incorporated by reference in this prospectus supplement. The Agent may sell the ordinary shares by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act. We may instruct the Agent not to sell ordinary shares if the sales cannot be effected at or above the price designated by us from time to time. We or the Agent may suspend the offering of ordinary shares upon notice and subject to other conditions.

The settlement between us and Chardan, as representative of the Agent, is generally anticipated to occur on the second trading day following the date on which the sale was made. Sales of our ordinary shares as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such other means as we and Chardan may agree upon. There is no arrangement for funds to be received in an escrow, trust, or similar arrangement.

We will